CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

GD2-Directed CAR T-Cell Therapy Elicits Durable Benefit in H3K27M-Mutated Diffuse Intrinsic Pontine Gliomas

April 10th 2022

GD2-directed CAR T-cell therapy demonstrated prolonged periods of radiographic and clinical improvement in pediatric and young adult patients with H3K27M-mutated diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas.

Off-the-Shelf Anti-Mesothelin CAR T-cell Therapy Improves In Vivo Activity Vs Gavo-Cel in Mesothelin-Expressing Tumors

April 10th 2022

Off-the-shelf anti-mesothelin T-cell receptor fusion construct T cells demonstrated prolonged persistence and efficacy in vivo against mesothelin-expressing tumors in mice, compared with gavocabtagene autoleucel.

Relmacabtagene Autoleucel Gets Breakthrough Therapy Designation for MCL in China

April 7th 2022

The China National Medical Products Administration’s Center for Drug Evaluation has granted a breakthrough therapy designation to relmacabtagene autoleucel for use in the treatment of patients with mantle cell lymphoma.

Lisocabtagene Maraleucel Approved in Europe for Select Relapsed/Refractory LBCL

April 5th 2022

The European Commission has granted marketing authorization to the CD19-directed CAR T-cell therapy lisocabtagene maraleucel for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B following 2 or more lines of systemic treatment.

FDA Grants Fast Track Status to PRGN-3006 for Relapsed/Refractory AML

April 4th 2022

The FDA has granted a fast track designation to the multigenic autologous CAR T-cell therapy PRGN-3006 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia.

Dr. Leslie on the FDA Approval of Axicabtagene Ciloleucel for Second-Line Relapsed/Refractory LBCL

April 1st 2022

Lori A. Leslie, MD, discusses the FDA approval of axicabtagene ciloleucel for second-line relapsed/refractory large B-cell lymphoma.

FDA Approves Axicabtagene Ciloleucel for Second-Line LBCL

April 1st 2022

The FDA has approved axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

CAR T-Cell Therapy May Represent a New Option in Medullary Thyroid Cancer

April 1st 2022

Investigators at the Perelman School of Medicine at the University of Pennsylvania have recently initiated a clinical trial evaluating a novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with advanced incurable medullary thyroid cancer.

Lisocabtagene Maraleucel sNDA for Second-Line Relapsed/Refractory LBCL Accepted for Review in Japan

March 26th 2022

The Ministry of Health, Labour, and Welfare has accepted a supplemental new drug application for lisocabtagene maraleucel for the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.

Tisagenlecleucel Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma

March 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of tisagenlecleucel for use in adult patients with relapsed/refractory follicular lymphoma following 2 lines of systemic treatment.

Cilta-cel Offers Durable Option for Heavily Pretreated Multiple Myeloma

March 23rd 2022

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma, following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Inside the Clinic: JTCC Experts Share Strategies for When CAR T-Cell Therapy Is Not an Option

March 15th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.

Inside the Clinic: JTCC Experts Discuss Approaches to CAR T-Cell Therapy

March 15th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss approaches to CAR T-cell therapy.

Inside the Clinic: JTCC Experts Highlight Optimal Strategies for CAR T-Cell–Related AEs

March 10th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss optimal strategies for CAR T-cell–related adverse effects.

Inside the Clinic: JTCC Experts Discuss Retreatment With CAR T-Cell Therapy

March 10th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

Inside the Clinic: JTCC Experts Highlight Next Steps With CAR T-Cell Therapy

March 9th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

FDA Approval of Cilta-Cel Fast Tracks Multiple Myeloma Toward Curative Potential

March 7th 2022

Sundar Jagannath, MBBS, discusses the significance of the FDA approval of ciltacabtagene autoleucel, important adverse effects to be aware of, and shared his thoughts on where the treatment fits into the current and future treatment paradigms.

Bispecific Antibodies Show Potential After Relapse on CAR T-cell Therapy in Myeloma

March 2nd 2022

Oliver Van Oekelen, MD, MSc, discusses findings from a retrospective study that evaluated treatment and efficacy outcomes in patients with relapsed or refractory multiple myeloma who experienced disease progression after BCMA-directed CAR T-cell therapy.

FDA Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma

March 1st 2022

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

FDA Grants Priority Review to Liso-cel for Second-Line Relapsed/Refractory LBCL

February 17th 2022

The FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of the CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma in whom frontline therapy has failed.